STAT4 and cancer: Since the activation and dimerization of STAT proteins requires binding to the SH2 domain, selective small-molecule inhibitors of the STAT4 SH2 domain represent potential new therapeutic agents for the treatment of autoimmune diseases [5] and molecular tools for the investigation of the role of STAT4 in cancer.